D. Anderson & Company (DAC), a global leader in patient recruitment and retention, has been named one of the 50 Largest Women-Owned Businesses in Dallas-Ft. Worth for 2008.
November 10, 2008 D. Anderson & Company (DAC), a global leader in patient recruitment and retention, has been named one of the 50 Largest Women-Owned Businesses in Dallas-Ft. Worth for 2008. The Dallas Business Journal bestows the coveted honor each year based on annual revenues and company size. Of 29,959 women-owned businesses in Dallas, according to the U.S. Census Bureau, DAC ranks 47th in terms of profits and personnel. President and CEO Diana Anderson, Ph.D., has positioned DAC as an international player boasting expertise in several therapeutic areas. The company began more than 18 years ago as a site management organization and evolved into one of the largest privately held patient recruitment and retention firms in the United States. DAC’s client list includes leading biotechnology and pharmaceutical companies worldwide. But it doesn’t end there. Urban hospitals, community clinics and private physicians call on DAC for strategic direction. The company reinforces its position as a thought leader by addressing delegates at key industry conferences worldwide and publishing authoritative books and articles. In 2007, DAC released “International Patient Recruitment Regulatory Guidelines, Customs and Practices,” which provides an expository view of legislation governing patient recruitment in 23 countries. This editorial endeavor elevated DAC’s profile on the international circuit. DAC is headquartered in Dallas with affiliate offices in Houston, Seattle and Windsor, U.K. For more information, visit www.dandersoncompany.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.